Downward revision in oxaliplatin injection ceiling price by NPPA following a review order

The National Pharmaceutical Pricing Authority (NPPA) has announced a downward revision in the ceiling price of oxaliplatin injection (5 mg/ml, 10 ml vial) under the Drugs (Prices Control) Order, 2013, incorporating the applicable Wholesale Price Index (WPI) adjustment for 2026.

The revision reduces the regulated ceiling price for the scheduled formulation. Manufacturers and importers must issue revised price lists in Form V through IPDMS and provide copies to the concerned authorities and dealers, while complying with applicable reporting and discontinuation requirements.

Join our 1500+ subscribers to get our daily Health Laws and Policy Updates.